Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna ductal lavage & ductoscopy Coverage Update |…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0517

    Breast Ductal Lavage and Fiberoptic Ductoscopy

    Customize your policy alerts

    Sign up for Aetna Policy 0517 alerts

    Get alerted when Policy 0517 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity and investigational positions for breast ductal lavage and fiberoptic ductoscopy, and the patient populations/procedures addressed (diagnosis of non-lactational sporadic nipple discharge, guidance of resection, and other uses). Applies to Aetna members and providers submitting claims to Aetna.

    Policy Summary
    PayerAetna
    PolicyBreast Ductal Lavage and Fiberoptic Ductoscopy
    Policy CodePolicy 0517
    Change TypeNo material changes
    Effective DateJun 15, 2001
    Last ReviewAug 5, 2026
    Next Review DateMay 27, 2027
    Key ActionObtain and document clinical indication and supporting diagnosis codes when submitting claims for ductal lavage or fiberoptic ductoscopy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3medically necessary interventions
    5experimental/unproven interventions
    19030,77053CPT codes referenced
    2026-08-05policy last reviewed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2001-06-15
    policy effective

    Coverage Criteria and Rationale

    Medically necessary

    Aetna considers the following interventions medically necessary:

    Medically necessary uses: 1) Breast ductal lavage as an appropriate alternative to aspiration to diagnose members with non-lactational sporadic nipple discharge when yield from direct nipple aspirate is too low for adequate cytological analysis; 2) Fiberoptic ductoscopy combined with cytology testing for diagnosing intra-ductal lesions in women with non-lactational sporadic nipple discharge; 3) Fiberoptic ductoscopy as a guide for resection of known breast intra-ductal cancer.

    Experimental, investigational, or unproven

    The following interventions are considered experimental, investigational, or unproven:

    Experimental/Investigational/Unproven uses: 1) Breast ductal endoscopy combined with ductal lavage for evaluation of the contralateral breast in women with ipsilateral breast cancer; 2) Breast ductal lavage (including named commercial tests/devices such as Pro‑Duct Catheter, ForeCYTE, MASCT, and Halo Breast Pap Test) for breast cancer screening, breast cancer risk assessment, and for all indications other than those listed as medically necessary; 3) Fiberoptic ductoscopy (Acueity System) for breast cancer screening; 4) Assessment of genetic methylation patterns in ductal lavage samples for prediction of breast cancer risk; 5) miRNA analysis of breast ductal fluid for detection of breast cancer.

    These uses are considered unproven because effectiveness has not been established.

    Coverage rationale and use-cases

    Evidence summary and context for clinical use

    General evidence-based stance: Ductal lavage and nipple aspiration tests have limited clinical utility due to frequent inadequate cellularity, inconsistent reproducibility, and uncertain predictive value; well‑designed longitudinal studies are needed to establish clinical significance.

    Supported by studies reporting high rates of inadequate samples, poor reproducibility, and limited sensitivity.

    Potential appropriate investigational or adjunctive uses: DL/NAF may be used in research settings for biomarker discovery (including metabolomic and miRNA analyses) and in selected clinical research protocols; fiberoptic ductoscopy may be considered diagnostically for evaluation of pathologic nipple discharge when imaging is inconclusive and to assist localization or resection of intraductal lesions.

    Examples in the literature: metabolomics and miRNA studies; FD sensitivity for malignant lesions up to 94.2% and increased when combined with cytology.

    Limitations to routine screening: NAF-based tests (e.g., ForeCYTE/MASCT/Halo) are not validated substitutes for mammography or clinical breast exam; FDA actions and limited clinical validation mean these tests should not be used for population screening.

    FDS combined with methylene blue — reported clinical outcomes

    Evidence-based observations from recent studies informing clinical use

    Findings supporting use of FDS with methylene blue: When fiberoptic ductoscopy is followed by immediate methylene blue injection and surgery performed 12–24 hours later, studies report improved localization of discharging ducts, smaller incision length, less tissue removal, lower intraoperative blood loss, shorter operation duration, shorter hospital stay, improved cosmetic satisfaction, and detection of malignancy even when imaging (ultrasound and mammography) is negative.timing: 12-24 hours

    Reported benefits observed in retrospective and prospective series; authors note sample limitations and recommend further study.

    Ductal fluid biomarker analysis (miRNA)

    Biomarker research using ductal fluid

    miRNA analysis feasibility: miRNA analysis of ductal lavage fluid is feasible and can identify differentially expressed miRNAs between tumor and paired normal samples; findings are promising but variable across studies and require further validation before clinical application.742 miRNAs screened in one study

    Study by Do Canto et al. (2016) identified 17 differentially expressed miRNAs from DL fluid but authors emphasize need for larger validation studies.

    Aetna excludes the use of ductal lavage, nipple aspiration tests, and fiberoptic ductoscopy when they are applied for population-based breast cancer screening, general risk assessment, or other indications that are not specifically listed as medically necessary in this policy. The policy lists these modalities (including named commercial systems such as ForeCYTE, MASCT, Pro-Duct Catheter, Halo, and Acueity) as experimental, investigational, or unproven for screening and risk-assessment uses because effectiveness has not been established.

    When ductal lavage or nipple aspiration is proposed as an alternative to standard screening (mammography, clinical breast exam) or to assess average- or high-risk asymptomatic populations, providers should be aware these applications are not supported by Aetna and may be denied if billed for screening or risk-assessment indications.

    NAF-based screening tests (for example, the ForeCYTE/MASCT/Halo systems) are not substitutes for established breast cancer screening modalities. The FDA has advised that nipple aspirate tests lack valid scientific data demonstrating they are effective screening tools, and Atossa/ForeCYTE received regulatory action including a warning letter and a voluntary recall.

    Because many commercial NAF systems yield scant or no cellular material in a large proportion of samples, a negative NAF cytology result does not reliably exclude malignancy and positive or indeterminate results may be non-diagnostic; therefore these tests should not replace mammography or clinical evaluation.

    Fiberoptic ductoscopy (FDS) can be limited or infeasible when there is no active nipple discharge because insertion of the ductoscope into a normal or non-discharging duct is difficult. Thin duct caliber, intraductal fibrous tissue or inflammatory secretions, and lesions located in terminal (distal) branches beyond the length/diameter of the ductoscope can prevent adequate visualization.

    Studies using FDS with adjunctive techniques note these technical limitations and recommend complementary imaging (high-frequency ultrasound, MRI, or mammography) when necessary. Additionally, timing and choice of dyes (e.g., methylene blue absorption after 72 hours) and a recognized learning curve for the procedure introduce further practical constraints to routine use.

    Ductal lavage and nipple aspiration tests have insufficient evidence to support their use as screening tests in high-risk or asymptomatic populations. Multiple federal and professional reviews (FDA, American Cancer Society, Institute of Medicine, BCBSA, CTAF) have concluded data are inadequate to recommend DL/NAF as independent screening modalities, and prospective trials assessing sensitivity, specificity, and impact on health outcomes are lacking.

    Commercial proponents acknowledge a high rate of samples with very scant or no cells (>90% in company reports), which undermines clinical utility and contributes to the conclusion that these methods are not validated for routine screening or risk assessment.

    Evidence from studies of women with known breast cancer indicates ductal lavage has low sensitivity for identifying existing malignancy. In a series where DL was performed on malignant breasts, only a minority of samples from malignant breasts contained abnormal cells, supporting the conclusion that DL is not an effective standalone test to detect existing breast cancer.

    Because of this low sensitivity in malignant breasts and frequent inadequate cellular yield, DL should not be relied upon as a primary diagnostic test for detecting established breast cancer.

    The extracted policy excerpts describe Aetna’s medical necessity and investigational positions and summarize supporting evidence, but they do not present an explicit, standalone paragraph framed as a formal not medically necessary determination within the provided excerpt. Instead, the policy lists specific medically necessary uses and enumerates interventions considered experimental, investigational, or unproven.

    Operationally, this means that while several applications are identified as investigational/unproven (and thus excluded from coverage for those indications), the document excerpt does not include a separate, explicit blanket statement labeled “not medically necessary” in the text segments provided here.

    CPT and ICD-10 Coding

    Other CPT codes related to the CPBCPT
    19030Injection procedure only for mammary ductogram or galactogram.
    77053Mammary ductogram or galactogram, single duct, radiological supervision and interpretation.
    77054Mammary ductogram or galactogram, multiple ducts, radiological supervision and interpretation.
    Cytopathology CPT codesCPT
    88104Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation.
    88106Simple filter method with interpretation.
    88108Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique).
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal.
    88160Cytopathology, smears, any other source; screening and interpretation.
    88161Preparation, screening and interpretation.
    88162Extended study involving over 5 slides and/or multiple stains.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C50.011-C50.A2Malignant neoplasm of breast (range as listed).
    D24.1-D24.9Benign neoplasm of breast (range as listed).
    D05.00-D05.12Intraductal carcinoma in situ of breast.
    N64.52Nipple discharge [non-lactational sporadic nipple discharge].
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    N61.0-N61.1Inflammatory disorders of breast [non-lactational mastitis].
    N63.0-N63.42Unspecified lump in breast.
    N64.3-N64.51, N64.53-N64.9Other disorders of breast.
    T85.44xA-T85.44xSCapsular contracture of breast implant.
    Z12.39Encounter for other screening for malignant neoplasm of breast.
    Z80.3Family history of malignant neoplasm of breast.
    Z85.3Personal history of malignant neoplasm of breast.
    Codes mentioned in this excerptmixed
    No codes listed
    Codes mentionedmixed
    No codes listed

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Prior authorization may be required for referenced procedure/cytology codes

    Obtain prior authorization for the procedure and cytology codes listed in this policy when required by the member's benefit plan; submit appropriate CPT/HCPCS codes (e.g., 19030, 77053, 77054, and cytopathology codes 88104–88162) for review per plan rules.

    • Prior authorization expectation is based on member benefit rules and the specific indication.
    Prior Authorization

    No explicit PA codes specified in policy excerpts — verify plan rules

    The policy excerpts do not specify formal prior authorization codes or an explicit universal PA requirement for ductal lavage or ductoscopy; check the member’s plan for any local PA rules or research/clinical-trial coverage exceptions.

    Prior Authorization

    Background and Procedure Overview

    Ductal lavage (DL) is a catheter-based procedure to obtain epithelial cells from individual breast ducts for cytologic examination. The technique involves cannulation of a ductal orifice at the nipple, infusion of saline to wash the ductal lumen, and collection of the lavage fluid for cytology.

    DL and related approaches (nipple aspiration, Halo-type collection systems) aim to sample ductal epithelial cells without excisional biopsy; however, yield is frequently low and procedures may be performed in operating-room or clinic settings depending on clinical context and the need for concurrent surgery or tissue diagnosis.

    Definitions

    Ductal lavage (DL) — definition of the procedure
    DefinitionProcedure in which epithelial cells are collected from individual breast ducts via identification of ductal orifices, catheter insertion, infusion of saline to wash the duct, and retrieval of saline with dislodged cells for cytologic examination.
    Typical stepsLocate natural duct openings, apply topical anesthetic, insert flexible microcatheter through the nipple duct, infuse saline, massage breast to dislodge cells, collect lavage fluid and submit cellular material for cytology.
    Clinical role (policy)Considered medically necessary as an alternative to aspiration to diagnose non-lactational sporadic nipple discharge when direct nipple aspirate yield is too low for adequate cytology.
    Device example / regulatory notePro-Duct catheter has been used to collect ductal epithelial cells and was cleared by the FDA via 510(k) (clearance does not require demonstration of effectiveness).
    Nipple aspiration fluid (NAF) / Halo system — definition and notes on yield
    Policy Summary
    PayerAetna
    PolicyBreast Ductal Lavage and Fiberoptic Ductoscopy
    Policy CodePolicy 0517
    Change TypeNo material changes
    Effective DateJun 15, 2001
    Last ReviewAug 5, 2026
    Next Review DateMay 27, 2027
    Key ActionObtain and document clinical indication and supporting diagnosis codes when submitting claims for ductal lavage or fiberoptic ductoscopy.
    SourceLink
    On This Page
    Coverage Criteria and RationaleCPT and ICD-10 CodingProvider Actions, Documentation, and Prior AuthorizationBackground and Procedure OverviewDefinitions

    Companies report >90% of samples may have scant or no cells; Halo study showed only 19% with adequate cellularity.

    No formal PA requirement stated for ductal lavage or ductoscopy

    The document does not state a formal, policy-wide prior authorization mandate for ductal lavage or fiberoptic ductoscopy; follow the member’s benefit contract and local PA processes if applicable.

    Note

    Unspecified provider action

    (Placeholder — no specific action detailed in source).

    Step Therapy

    Imaging sequence: HFUS first; FDS as complementary/localization tool

    When evaluating pathologic nipple discharge, perform high-frequency ultrasound (HFUS) as the preferred first-line imaging; consider fiberoptic ductoscopy (FDS) when HFUS is non-diagnostic or to complement localization.

    • HFUS is preferred first-line evaluation for patients with nipple discharge.
    • Consider FDS if HFUS cannot identify the cause of pathologic nipple discharge.
    Step Therapy

    No formal step therapy specified; use complementary imaging as clinically indicated

    No step-therapy or mandatory sequencing is specified in the policy; use complementary imaging (US, mammography, MRI) as clinically appropriate before or alongside ductoscopy per cited study recommendations.

    • Policy excerpts report studies recommending complementary imaging when necessary prior to or in conjunction with ductoscopy.
    • No formal step-therapy requirements are listed in the document.
    Documentation Required

    Document specific clinical indication and supporting diagnosis codes on claims

    When submitting claims for the CPT/HCPCS codes referenced in this policy, document the specific clinical indication (for example, non-lactational sporadic nipple discharge) and include supporting ICD-10 diagnosis codes to justify medical necessity.

    • Examples of covered diagnosis codes include malignant neoplasm of breast (C50.*), benign neoplasm (D24.*), intraductal carcinoma in situ (D05.*), and N64.52 (nipple discharge).
    Documentation Required

    Record cannulation success, cell-yield adequacy, and cytologic findings

    Document procedural details for lavage and cytology submissions: record successful cannulation, adequacy of cell yield (report if samples were scant or insufficient), and detailed cytologic findings because studies frequently report inadequate cellularity and variable reproducibility.

    • Record whether cannulation of the target duct was successful.
    • Indicate cell yield adequacy (e.g., sufficient epithelial cells or inadequate/scant cellularity).
    • Include cytologic interpretation and any inter-observer review results if performed.
    Documentation Required

    When using FDS with methylene blue, document timing, ductoscopic findings, and correlated imaging

    If FDS is performed with immediate methylene blue injection, document the timing of methylene blue injection relative to surgery (studies report optimal surgery 12–24 hours after injection), ductoscopic findings (lesion morphology, location, hemorrhage, duct wall characteristics), and imaging results used for correlation.

    • Note exact timing of methylene blue injection and interval to surgery (12–24 hours reported as optimal).
    • Describe ductoscopic lesion features and duct wall appearance.
    • Attach correlated imaging (US, mammography) results when available.
    Denial Risk

    Risk of claim denial if codes are used for not-covered indications

    Claims using the policy’s procedure or cytology codes for indications listed as not covered (for example, screening, family-history-only, unspecified breast lumps, or inflammatory breast conditions) may be denied; confirm the coded indication matches a covered use before submission.

    • ICD-10 codes listed as not covered include screening (Z12.39), family history (Z80.3), personal history (Z85.3), unspecified lump (N63.*), and inflammatory disorders (N61.*) per the policy listings.
    Denial Risk

    NAF samples often yield scant/no cells — document sample adequacy

    Be aware that nipple aspiration and NAF collection tests commonly produce very scant or no cells — companies report over 90% of samples may be scant/acytologic — and such insufficient samples may be diagnostically unhelpful and affect coverage determination for clinical utility.

    • Studies and company reports note >90% of NAF samples may contain very scant or no cells, limiting diagnostic value.
    • Document and report sample inadequacy on the claim to support clinical context.
    Note

    No additional explicit provider-authorization or denial triggers stated in excerpts

    The cited excerpts do not identify specific provider authorization triggers or unique denial criteria beyond the documentation, coverage, and indication-based denial risks noted above; follow the member’s benefit rules and policy coding guidance.

    DefinitionNoninvasive collection of nipple fluid using gentle suction devices (e.g., Halo) that apply warmth, compression and vacuum to retrieve nipple aspirate fluid (NAF) for cytological evaluation.
    Device exampleHalo NAF Collection System / Halo Breast Pap Test: an office-based, automated device using adjustable cups, heat, mild compression and a 5-minute cycle to generate and collect NAF.
    Yield and adequacyIn a prospective multicenter study of 500 asymptomatic women, 38% produced fluid, 19% produced NAF with adequate cellularity, and 1% showed cytological atypia; 50% of samples were category 0 (insufficient cellular material).
    LimitationTypically yields only tiny amounts of fluid and few cells, limiting cytologic and biomarker analyses in many subjects.
    Fiberoptic ductoscopy — definition and brief summary
    DefinitionEndoscopic visualization of the breast ductal system using a small fiberoptic scope inserted through the nipple ductal orifice to directly visualize intraductal anatomy and detect abnormalities.
    Adjunct functionsMay be combined with ductal lavage or cytology to obtain cellular samples and can assist in diagnosis of intraductal lesions or guide resection.
    Research / devicesAcueity System (microendoscopic intraductal visualization) is used in research and clinical trials but lacks randomized, well-controlled evidence demonstrating safety and effectiveness for screening or broad diagnostic use.
    Nipple aspirate fluid (NAF) / Halo Breast Pap Test — device/system definition
    DefinitionAutomated system (Halo Breast Pap Test) to collect nipple aspirate fluid (NAF) via adjustable breast cups that apply heat, mild compression and gentle suction during a short cycle to retrieve fluid for cytological evaluation.
    Intended use claimManufacturer describes the Halo system as an office-based, noninvasive test designed to detect abnormal ductal epithelial cells potentially years earlier than mammography or self-exam (manufacturer claim).
    Performance in studyIn a multicenter observational study, Halo was safe, rapid and acceptable to patients, but produced adequate cellularity in only 19% of all subjects, limiting its utility for screening.
    Fiberoptic ductoscopy (FD) — definition focused on scope insertion and visualization
    DefinitionInsertion of a small fiberoptic scope into the nipple ductal orifice to directly visualize the intraductal lumen and detect abnormalities; scope diameter approximates the size of a pencil tip and can visualize lesions down to ~0.1 mm in some systems.
    Visualization purposeUsed to inspect ductal mucosa, identify intraductal lesions, and guide targeted ductal excision or further sampling (often combined with lavage or instrumented biopsy).
    LimitationsFeasibility may be limited when there is no active discharge, ducts are very small or obstructed, or lesions are beyond the ductoscope’s reach; some systems remain investigational for screening purposes.
    MicroRNA analysis of ductal fluid — definition of miRNA testing in ductal fluid
    DefinitionMolecular testing approach that measures expression of microRNAs in ductal lavage or nipple aspirate fluid to identify miRNAs differentially expressed between tumor and paired normal samples.
    Evidence statusFeasible in small studies (example: real-time PCR array screening of 742 miRNAs in DL fluid from 22 women identified 17 differentially expressed miRNAs), but findings are preliminary with variability across cohorts and require validation.
    Potential roleInvestigational biomarker method for detection or characterization of breast cancer using minimally invasive ductal fluid sampling rather than tissue biopsy or blood, but not established for clinical use.
    Immediate methylene blue staining after FDS — definition and surgical localization use
    DefinitionInjection of methylene blue dye into discharging ducts immediately after fiberoptic ductoscopy (FDS) to stain and localize the diseased duct for subsequent surgery performed typically 12–24 hours later.
    Reported clinical effectsStudies reported improved localization of diseased ducts, smaller incision length, less tissue resection, lower intraoperative blood loss, shorter operation time, better cosmetic satisfaction, and facilitation of selective ductectomy with detection of malignancy even when imaging is negative.
    Timing considerationOptimal dyeing without overflow was achieved when surgery was performed 12–24 hours after immediate methylene blue injection; authors note dye absorption over longer intervals and study limitations.